Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
The Japan Pharmaceutical Manufacturers Association (JPMA) on April 1 announced a broad policy for its activities in FY2025, reiterating the need for the Japanese government to break away from its overdependence on drug price cuts in making its social security…
To read the full story
Related Article
- MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- JPMA to Put Japan’s Social Security Spending Cap Up for Discussion: Exec
February 21, 2025
ORGANIZATION
- US VC Coalition Urges Japan to Rethink Drug Pricing, Labor Rules
October 13, 2026
- PhRMA Sues CMS over Medicare MFN Model, Calls It Unlawful Overreach
October 9, 2026
- Japan Generic Group Calls for Clearer Patent Extension Rules
October 9, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- JPMA Chief Urges Manufacturing, Talent Push to Build Drug Discovery Ecosystem
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…